Operator
Greetings, and welcome to the Ensysce Biosciences, Inc. Corporate Update Call. [Operator Instructions] It is now my pleasure to introduce your host, Dr. Lynn Kirkpatrick, Chief Executive Officer. Thank you. You may begin.
D. Kirkpatrick
President, CEO & Director
Thank you, operator, and good morning, everyone. Thank you for joining us. We recently issued a press release outlining our acquisition of Cy Biopharma and a concurrent private placement financing. That release, along with an updated corporate presentation, is available at www.ensysce.com under the Investors Section.
Before we begin, I would like to remind everyone that the statements made during this call that are not historical facts, including statements relating to Ensysce’s expected future performance, future business prospects and future events or plans and the anticipated benefits of the transaction, may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
All such forward-looking statements are intended to be subject of the safe harbor protection provided by the Reform Act. These statements are based on current expectations and are subject to risks and uncertainties that could cause actual outcomes and results to differ materially from those forecast due to the impact of many factors beyond the control of Ensysce. Ensysce undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Participants are directed to the risk factors set forth in Ensysce’s filings and the Securities and Exchange Commission including in its most recent Form 10-K and Form 10-Q and in other filings that it makes with the U.S. Securities and
Read the full article here